GSK's pharmaceutical sales adversely affected by generic competition
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's third-quarter results have improved from the previous quarter this year, with pharmaceutical sales growing by 6% in pound sterling to £4.9 billion. The results were 3% better than Dresdner Kleinwort's estimates, but generic competition, particularly in the US, remains a challenge to future growth.